Bio-Works Technologies AB appoints Eva Lindskog as new CEO

Uppsala 18 August 2026

The Board of Directors of Bio-Works Technologies AB has appointed Eva Lindskog as Chief Executive Officer, effective 1 November 2026

Eva Lindskog succeeds Lone Carlbom, who, having previously served as Director of Products, will return to an operational role continuing to play an active part in the company’s operations alongside the CEO.

“Eva Lindskog has extensive experience from the life sciences industry, having worked across the biopharmaceutical value chain. She brings deep industry insights together with a strong track record of building commercial capabilities and driving growth, underpinned by an extensive and well-established international network. We are very pleased to welcome her as CEO and believe that her experience, leadership and commercial focus make her particularly well suited to lead Bio-Works through its next stage of development,” says Peter von Ehrenheim, Chair of the Board of Bio-Works

“I would also like to express the Board’s appreciation to Lone Carlbom. She stepped out of her previous operational role to take on the responsibility as CEO at an important time for the company and has done an excellent job in guiding Bio-Works through a pivotal period. We are very pleased that Lone will remain with the company and return to an operational role, where her experience and expertise will continue to be of great value”, von Ehrenheim concludes.

Lone Carlbom comments:

“I am grateful for the trust placed in me and for the opportunity to have led Bio-Works through a crucial phase in its development. I am very proud of what we have achieved together and look forward to continuing to contribute to the company’s progress and to working closely with Eva going forward.”

Eva Lindskog comments:

“Bio-Works has a solid technology foundation, clearly differentiated products and a highly committed team. As we enter the next stage of Bio-Works' journey, I believe success will depend on strengthening our relationships with customers even further. I intend to be personally at the forefront of those efforts, working directly with end users to ensure that the value of our products is fully understood. Successful businesses are built by solving real customer problems, and that is the opportunity that excites me most about Bio-Works.”

In connection with this announcement, Eva Lindskog will also step down from the Board of Directors of Bio-Works Technologies AB.

About Eva Lindskog

Eva Lindskog has more than 20 years of global experience in the life sciences industry. She has held executive and senior leadership roles at Sartorius, Lonza, and GE Healthcare Life Sciences, leading commercial organizations and strategic growth initiatives across the biopharmaceutical market.

Eva has built her career at the intersection of science and business, helping life science companies translate innovation into commercial success. Eva holds a PhD in Bioprocess Technology and an MSc in Chemical Engineering from KTH Royal Institute of Technology in Sweden. Most recently, she served as Chief Commercial Officer at NanoTemper Technologies.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Peter Ehrenheim, Chairman, e-mail: peter@farjsundet.se, phone: +46 (70) 667 5711.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.

This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-08-2026 09:00 CET.